Publications by authors named "E Meduri"
Initial clinical trials with drugs targeting epigenetic modulators - such as bromodomain and extraterminal protein (BET) inhibitors - demonstrate modest results in acute myeloid leukemia (AML). A major reason for this involves an increased transcriptional plasticity within AML, which allows cells to escape the therapeutic pressure. In this study, we investigated immediate epigenetic and transcriptional responses following BET inhibition and could demonstrate that BET inhibitor-mediated release of BRD4 from chromatin is accompanied by an acute compensatory feedback that attenuates down-regulation, or even increases expression, of specific transcriptional modules.
View Article and Find Full Text PDFArticle Synopsis
- Fibrinolysis plays a crucial role in the release of hematopoietic stem cells from bone marrow, affecting the development of B-cell acute lymphoblastic leukemia (B-ALL).
- Activation of plasmin, driven by annexin A2, alters the extracellular matrix (ECM), which impacts cancer cell growth by trapping the growth factor IGF1 and hindering signaling pathways.
- Inhibiting plasmin activation with ε-aminocaproic acid (EACA) shows promise in reducing tumor size and extending survival in B-ALL models, suggesting that targeting fibrinolysis could be a helpful addition to cancer treatment.
Inflammation promotes solid tumor progression, but how regulatory mechanisms of inflammation may affect leukemia is less well studied. Using annexin A5 (ANXA5), a calcium-binding protein known for apoptosis, which we discovered to be differentially expressed in the bone marrow microenvironment (BMM) of mice with acute myeloid (AML) vs chronic myeloid leukemia, as a model system, we unravel here a circuit in which AML-derived tumor necrosis factor α (TNF-α) dose-dependently reduces ANXA5 in the BMM. This creates an inflammatory BMM via elevated levels of prostaglandin E2 (PGE2).
View Article and Find Full Text PDFTo investigate biomarkers of intra-ocular pressure (IOP) decrease after cataract surgery with trabecular washout in pseudo-exfoliative (PEX) glaucoma. A single-center observational prospective study in PEX glaucoma patients undergoing cataract surgery with trabecular washout (Goniowash) was performed from 2018 to 2021. Age, gender, visual acuity, IOP, endothelial cell count, central corneal thickness, medications, were collected over 16-month follow-up.
View Article and Find Full Text PDF